• Blog
  • Chronic Idiopathic Constipation (CIC) Drugs Market Report

    Chronic Idiopathic Constipation (CIC) Drugs Market Report

    Chronic Idiopathic Constipation (CIC) Drugs Market Report
    Report code - SR1553 Delivery - 2 Weeks
    Chronic Idiopathic Constipation (CIC) Drugs Market Trends, Dynamics & Market Insights: See more...

    Market Insights

    The Chronic Idiopathic Constipation (CIC) Drugs market is projected to grow from USD 4.38 billion in 2021 to USD 6.93 billion by 2028 at a CAGR of around 6.72% during the forecast period of 2022-2028.

    Chronic-Idiopathic-Constipation-Drugs-Market-Size

    What is constipation?

    Constipation is defined as a health condition with decreased stool frequency or issues in passant stool. Reduced or tough stool passage is during hard lumpy stools, straining, incomplete bowel actions, incomplete evacuation, and the necessity for manual elimination of stool. Chronic idiopathic constipation (CIC) is defined as a persistent or extreme continuation of the above-mentioned signs and symptoms.

    Market Drivers

    The growth of the chronic idiopathic constipation (CIC) drugs market is primarily driven by increasing incidences of chronic constipation health disorder. Expanding geriatric populace across geographies coupled with rising spending on healthcare is expected to propel the market growth at a significant rate during the review period. Additionally, a growing emphasis on research and development activities for novel drug development is likely to create lucrative opportunities for the market players during the review period.

    COVID-19 Impact on Chronic Idiopathic Constipation (CIC) Drugs Market

    The outbreak of the COVID-19 virus has affected the growth of the healthcare industry significantly. Stringent lockdown measures and restricted movement of people affected the product supply for a short period and thus, affected the market growth.

    Chronic-Idiopathic-Constipation-Drugs-Market-Snapshot

    Wish to get a free sample? 

    Key Players

    Key players operating in the Chronic Idiopathic Constipation (CIC) Drugs market are-

    • Actavis Generics (US)
    • The Chugai Pharmaceutical Co., Ltd (Japan)
    • Ferring International Center, S.A. (Switzerland)
    • Synergy Pharmaceuticals (US)
    • Pfizer Inc. (US)
    • GlaxoSmithKline plc (UK)
    • F. Hoffmann-La Roche AG (Switzerland)
    • Sanofi S.A. (France)
    • Bayer AG (Germany)
    • Salix Pharmaceuticals, Inc. (US)
    • Sucampo Pharmaceuticals, Inc. (US)
    • Ironwood Pharmaceuticals, Inc (US)
    • Progenics Pharmaceuticals, Inc. (US).

    Segment Analysis

    End-User Trends

    By end-user, the chronic idiopathic constipation (CIC) drugs market has been bifurcated into hospitals & clinics, ambulatory surgical centers, long-term care centers, and others. Under these, the hospitals & clinics segment accounted for the largest market share in 2021 and is projected to register significant growth during the review period.

    Regional Trends

    By region, the market in North America accounted for the largest market share in 2021 and is projected to grow at a significant CAGR during the assessment period. The regional growth is primarily attributed to the high prevalence of chronic constipation particularly among the geriatric populace coupled with the presence of key market players such as Actavis Generics (US) and Pfizer Inc. (US). The market growth in the Asia-Pacific region is expected to be driven by rising awareness among consumers regarding CIC drugs coupled with the rising geriatric population in developing countries, particularly China and India.

    Research Methodology

    This report offers high-quality insights and is the outcome of detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact book, press release, journals, investor presentation, white papers, patents, and articles have been leveraged to gather the data. We conducted more than 10 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both the qualitative and quantitative insights.

    Report Features

    This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision making for the existing market players as well as those willing to enter the market. The following are the key features of the report:

    • Market structure: Overview, industry life cycle analysis, supply chain analysis
    • Market environment analysis: Growth drivers and constraints, Porter’s five forces analysis, SWOT analysis
    • Market trend and forecast analysis
    • Market segment trend and forecast
    • Competitive landscape and dynamics: Market share, product portfolio, product launches, etc.
    • Attractive market segments and associated growth opportunities
    • Emerging trends
    • Strategic growth opportunities for the existing and new players
    • Key success factors

    Target Audience

    Here is the list of the group of customers that the Chronic idiopathic constipation (CIC) Drugs Market hopes to have the greatest opportunity to convert-

    • Chronic idiopathic constipation (CIC) Drugs distributors
    • Chronic idiopathic constipation (CIC) Drugs suppliers
    • Chronic Idiopathic Constipation (CIC) Drugs manufacturers
    • Logistics organizations
    • Government bodies

    Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at sales@stratviewresearch.com.

    Frequently Asked Questions (FAQs)

    The chronic idiopathic constipation drugs market is expected to witness an impressive growth of 6.72% CAGR during 2022-2028.

    Actavis Generics (US), The Chugai Pharmaceutical Co., Ltd (Japan), Ferring International Center, S.A. (Switzerland), Synergy Pharmaceuticals (US), Pfizer Inc. (US), GlaxoSmithKline plc (UK), F. Hoffmann-La Roche AG (Switzerland), Sanofi S.A. (France), Bayer AG (Germany), Salix Pharma-ceuticals, Inc. (US), Sucampo Pharmaceuticals, Inc. (US), Ironwood Pharmaceuticals, Inc (US) and Progenics Pharmaceuticals, Inc. (US) are among the key players in the market.

    The chronic idiopathic constipation drugs market size is expected to reach USD 6.93 billion in 2028.

    The hospitals & clinics segment is expected to register significant growth in the market in the coming years.

    North America accounted for the largest share in the market in 2021.

    Chronic idiopathic constipation (CIC) Drugs distributors, Chronic idiopathic constipation (CIC) Drugs suppliers, Chronic Idiopathic Constipation (CIC) Drugs manufacturers, Logistics organizations, Government bodies are the target audience in the market.